<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30583">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708576</url>
  </required_header>
  <id_info>
    <org_study_id>15-0201</org_study_id>
    <nct_id>NCT02708576</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of NGM313 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of NGM313, both single
      dose and multiple doses, in normal healthy overweight and obese adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in weight in kilograms</measure>
    <time_frame>28 and 84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in fasting glucose in mmol/L</measure>
    <time_frame>28 and 84 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability as measured by adverse events, vitals signs, electrocardiograms, and clinical laboratories</measure>
    <time_frame>28 and 84 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics as measured by maximum observed concentration (cmax).</measure>
    <time_frame>28 and 84 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics as measured by time to maximum concentration (tmax).</measure>
    <time_frame>28 and 84 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics as measured by area under the curve (auc).</measure>
    <time_frame>28 and 84 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>NGM313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of active NGM313</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM313</intervention_name>
    <arm_group_label>NGM313</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI range 27-40 kg/m2, inclusive for the SAD module, and 27-40 kg/m2, inclusive for
             the MAD module;

          -  Normal clinical laboratory evaluations

          -  Normal ECG findings

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any significant metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, or psychiatric disorder

          -  Uncontrolled hypertension defined as sitting blood pressure systolic &gt; 150 mm/Hg
             and/or diastolic &gt; 90 mm/Hg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Que Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>February 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
